Roche And Broad Institute Begin Multi-Year Drug-Repurposing Program
This article was originally published in The Pink Sheet Daily
Roche and the Broad Institute have teamed up to resurrect drugs that failed in mid-stage drug trials in hopes of finding new niche patient populations that could benefit from them.
You may also be interested in...
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.
The biotech confirmed that a recent death during a clinical trial was not caused by its early-stage gene therapy.